投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 活动参与人员 线上参与 2023 年厦门辖区上市公司投资者网上集体接 待日的投资者 时间 2023 年 05 月 12 日（星期五）下午 14:30-16:15 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 形式 网络远程交流 上市公司接待人员 姓名 董事长兼总经理：吴金祥先生 董事、副总经理兼财务总监：杨聪金女士 独立董事：叶少琴女士 董事会办公室主任兼董事会秘书：叶泉青先生 交流内容及具体问 答记录 1、请问董事长，合作研发的心电仪市场推广成效如何？ 预计今年的利润贡献率是多少？ 答：公司根据市场情况制定业务发展策略，推动业务增 长，谢谢。 2、请问董事长，今年对鹭燕医药的市值管理有什么新举 措？ 答：公司一方面将持续提高公司的核心竞争力，提高运 营效率，扩大市场份额，实现业绩持续增长；另一方面， 公司将严守合规底线，规范运作，不断提高内部控制水 平，完善法人治理结构；通过不断提升公司价值实现公 司市值的增长。 | | 3、请 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 4,841,503,352.57, representing a 4.40% increase compared to CNY 4,637,268,373.59 in the same period last year[5] - Net profit attributable to shareholders was CNY 79,861,688.20, an increase of 11.37% from CNY 71,706,561.12 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 4,841,503,352.57, an increase of 4.4% compared to CNY 4,637,268,373.59 in Q1 2022[23] - Net profit for Q1 2023 reached CNY 78,600,499.56, compared to CNY 71,333,431.99 in Q1 2022, representing a growth of 10.1%[24] - The net profit attributable to the parent company was CNY 79,861,688.20, an increase from CNY 71,706,561.12 in the previous year, marking a rise of 11.5%[24] - Basic earnings per share for Q1 2023 were CNY 0.21, up from CNY 0.18 in Q1 2022[24] Cash Flow - The net cash flow from operating activities increased by 127.21%, reaching CNY 113,401,415.76, compared to a negative cash flow of CNY -416,697,576.75 in the previous year[5] - Cash inflow from operating activities totaled ¥5,408,013,910.72, compared to ¥4,650,047,143.44 in the prior period, reflecting a year-over-year increase of approximately 16.3%[27] - Cash outflow from operating activities was ¥5,294,612,494.96, up from ¥5,066,744,720.19, indicating a rise of about 4.5%[27] - The ending balance of cash and cash equivalents was ¥341,124,938.55, up from ¥255,336,795.43, marking an increase of approximately 33.5%[28] - The company paid ¥68,752,595.94 in dividends and interest, compared to ¥44,527,421.71 in the previous period, reflecting a rise of about 54.3%[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,349,841,193.41, a decrease of 3.68% from CNY 11,783,796,364.82 at the end of the previous year[5] - Total liabilities decreased to CNY 8,488,723,106.98 from CNY 8,993,147,283.00 year-on-year[21] - The company's total equity increased to CNY 2,861,118,086.43, compared to CNY 2,790,649,081.82 in the previous year[21] - Total current assets decreased from 9.75 billion yuan to 9.29 billion yuan, a decline of approximately 4.7%[17] Accounts Receivable and Inventory - Accounts receivable increased by 604.75% to CNY 3,347,600.00, primarily due to received bills not being endorsed or discounted[9] - Accounts receivable increased slightly from 5.84 billion yuan to 5.85 billion yuan, indicating a marginal growth of 0.03%[17] - Inventory decreased from 2.55 billion yuan to 2.38 billion yuan, representing a reduction of about 6.7%[17] Legal Matters - The company has initiated legal proceedings to recover 39.69 million yuan in damages from Guizhou Mingrun Construction Engineering Co., Ltd. and Chengdu Hechuang Ruida Enterprise Management Co., Ltd.[16] - The company has successfully enforced the collection of 8 million yuan in breach of contract damages from Guizhou Mingrun Construction Engineering Co., Ltd.[15] - Chengdu Hechuang has filed a new lawsuit seeking compensation of 31.63 million yuan plus interest from the aforementioned companies[16] Research and Development - Research and development expenses for Q1 2023 were CNY 769,300.60, up from CNY 602,864.18 in Q1 2022, indicating a focus on innovation[23] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of CNY -441,714.34 for Q1 2023 compared to CNY -279,198.76 in Q1 2022[24] - The company reported a significant increase in other current assets, which rose by 67.05% to CNY 66,615,100.00, attributed to an increase in input tax credits[9] - The balance of prepayments decreased by 37.71% to CNY 391,556,800.00, mainly due to the settlement of a large amount of prepaid epidemic prevention material payments[9] - The company has actively explored new financing tools such as supply chain financing and factoring, contributing to improved cash flow management[9]

Financial Performance - The company's operating revenue for 2022 was ¥19,462,501,277.53, representing a 10.93% increase compared to ¥17,545,397,267.57 in 2021[18]. - The net profit attributable to shareholders for 2022 was ¥345,155,498.99, up 12.84% from ¥305,870,612.74 in 2021[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥340,489,265.34, an 18.34% increase from ¥287,727,554.44 in 2021[18]. - The net cash flow from operating activities improved significantly to ¥232,186,445.57, a 162.41% increase from a negative cash flow of ¥372,020,787.97 in 2021[18]. - The total assets at the end of 2022 were ¥11,783,796,364.82, reflecting a 17.92% increase from ¥9,992,695,467.80 at the end of 2021[18]. - The net assets attributable to shareholders increased by 9.20% to ¥2,720,812,852.98 from ¥2,491,664,451.63 in 2021[18]. - The basic earnings per share for 2022 were ¥0.89, up 12.66% from ¥0.79 in 2021[18]. - The weighted average return on equity for 2022 was 13.01%, an increase from 11.82% in 2021[18]. Revenue Breakdown - The pharmaceutical wholesale segment generated ¥18,191,799,102.85, accounting for 93.47% of total revenue, with a year-on-year growth of 10.28%[54]. - The retail pharmaceutical segment saw revenue of ¥847,422,246.95, reflecting a significant increase of 17.86% from the previous year[54]. - The company’s pharmaceutical distribution business grew by 10.28% despite the adverse impact of centralized procurement policies[40]. - Medical device sales revenue increased by 16.64% during the reporting period[40]. - Retail business sales revenue saw a year-on-year growth of 17.86%[41]. - The company achieved total operating revenue of CNY 1,946,250.13 million, a year-on-year increase of 10.93%[38]. Market Presence and Expansion - The company ranked 15th among the top 100 pharmaceutical wholesale enterprises in China in 2021, maintaining its position as the largest pharmaceutical distribution company in Fujian Province[30]. - The company has achieved 100% coverage of secondary and higher medical institutions in Fujian Province since 2009, enhancing its market presence[34]. - The company is actively expanding its market presence in Sichuan, Jiangxi, and Hainan provinces through acquisitions, strengthening its competitive edge[34]. - The company has established a distribution and logistics network covering all public medical institutions in Fujian Province, with over 95% coverage in secondary hospitals in Sichuan, Jiangxi, and Hainan provinces[45]. - The company is committed to expanding its market presence beyond Fujian province, aiming for sustainable growth through both internal and external strategies[90]. Research and Development - Research and development expenses rose to ¥4,146,496.57, marking a significant increase of 39.51% compared to ¥2,972,163.26 in 2021[65]. - The number of R&D personnel increased by 27.27% from 11 to 14, with a notable rise in the number of staff under 30 years old[67]. - The company is currently developing several new products, including a portable fetal heart monitoring device and an AI-based cardiac ultrasound diagnostic system[66]. - The company is increasing R&D investment in modern traditional Chinese medicine to expand product variety and production capacity, while promoting the construction of the Luyan Bozhou Traditional Chinese Medicine Industrial Park[93]. Operational Efficiency - The gross profit margin for pharmaceutical products was 6.95%, showing a slight decrease of 0.11% compared to the previous year[56]. - The total operating costs amounted to ¥16,926,820,791.07, which is 94.31% of total operating costs, up by 10.41% from the previous year[58]. - The company reported a 30% increase in operational efficiency due to new technologies implemented in the production process[175]. - The company aims to reduce operational costs by 5% through strategic initiatives in the next fiscal year[175]. Governance and Compliance - The governance structure of the company complies with relevant laws and regulations, with regular meetings held to ensure effective management and risk control[97]. - The company has established a financial control mechanism to guide business management and optimize investment models, focusing on risk control in mergers and acquisitions[91]. - The company emphasizes the importance of internal control and risk prevention mechanisms to adapt to market policy changes and enhance compliance management[91]. - The company has not reported any penalties from securities regulatory agencies for its directors and supervisors in the past three years[116]. Shareholder Engagement - The company plans to implement a three-year shareholder return plan from 2022 to 2024[102]. - A cash dividend of 3.00 CNY per 10 shares (including tax) was approved, with a total cash dividend amounting to 116,555,020.80 CNY, representing 100% of the profit distribution[130]. - The company held a temporary shareholders' meeting on January 10, 2022, with a participation rate of 39.86%[102]. - The annual shareholders' meeting on May 17, 2022, also had a participation rate of 39.82%[102]. Social Responsibility - The company has maintained a focus on social responsibility, particularly in healthcare support during the pandemic[143]. - The company processed and delivered nearly 7 million bags of traditional Chinese medicine during the pandemic, supporting local governments and healthcare institutions[37]. - The company distributed 100,000 tablets of ibuprofen for free through its pharmacies to address public demand during shortages[143]. Future Outlook - The company projects a revenue growth of 10% for the upcoming fiscal year, aiming for a target of approximately 4,761 million[175]. - Future guidance indicates a projected revenue growth of 10% for 2023, driven by new product launches and market expansion strategies[179]. - The company plans to expand its market presence with new product launches and technological advancements in 2023[184].

证券代码：002788 证券简称：鹭燕医药 公告编号：2023-013 鹭燕医药股份有限公司 关于举行 2022 年年度报告网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 鹭燕医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者进一步了解公司 2022 年年度经营情况，公司定于 2023 年 4 月 21 日 （星期五）下午 15：00-17：00 举行 2022 年年度报告网上业绩说明会。本次业绩说明会将 采用网络远程交流的方式举行，投资者可登陆"鹭燕医药投资者关系"小程序参与互动交流。 为广泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之日起开放。 参与方式一：在微信中搜索"鹭燕医药投资者关系"小程序； 参与方式二：微信扫一扫以下二维码： 2023 年 4 月 18 日 投资者依据提示，授权登入"鹭燕医药投资者关系"微信小程序，即可参与交流。 出席 ...

证券代码：002788 证券简称：鹭燕医药 鹭燕（福建）药业股份有限公司 投资者关系活动记录表 编号：2016-007 | --- | --- | --- | |-----------------------|-------------------------|----------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称 | 中金公司：邹朋、屠炜颖 | | | 及人员姓名 | | | | 时间 | 2016 年 6 月 17 | 日上午 9:30-11:00 | | | | | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 投资者关系活 | 1 | 、三明医改模式对医药流通市场的主要影响。 | ...

证券代码：002788 证券简称：鹭燕医药 鹭燕（福建）药业股份有限公司 投资者关系活动记录表 编号：2016-005 | --- | --- | --- | |-----------------------|-------------------------|----------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □ 现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称 | | 西南证券：施跃、朱国广、张肖星 | | 及人员姓名 | 汇添富：张韡 | | | 时间 | 2016 年 5 月 31 | 日下午 15:00-16:30 | | | | | | 地点 | 鹭燕医药会议室 | | | 上市公司 接待人员姓名 | | 副总经理兼董事会秘书雷鸣、证券事务代表阮翠婷 | | 投资者关系活 | 1 、公司 2012 | 年业绩呈快速增长趋势，而 ...